RYTM PEER ANALYSIS

Rhythm Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

RYTMRhythm Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RYTMIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RYTM	TLX	CSL	MSB	Ind. Median
P/E	—	—	29.44	—	17.91
P/B	63.14	6.37	2.20●	—	3.51
EV/EBITDA	—	120.14	10.21●	—	14.82
P/S	35.74	3.24	2.62●	31.61	10.89

Financial Health
Metric	RYTM	TLX	CSL	MSB	Ind. Median
Current Ratio	4.17●	1.43	2.57	—	5.90
Debt/Equity	184.7%	112.3%	67.4%●	—	10.9%
NetDebt/EBITDA	0.63●	13.13	2.22	—	1.15

Profitability
Metric	RYTM	TLX	CSL	MSB	Ind. Median
Net Margin	-93.3%	-0.9%	9.2%●	-115.3%	-125.7%
ROE	-141.7%	-1.8%	7.7%●	-11.3%	-47.5%
ROA	-48.9%	-0.7%	3.8%●	-8.6%	-35.8%
EBITDA Margin	-83.2%	3.0%	32.8%●	-76.6%	-105.8%

Growth + Dividend
Metric	RYTM	TLX	CSL	MSB	Ind. Median
Rev. Growth	58.7%	56.3%	4.8%	410.4%●	5.1%
NI Growth	—	—	-39.4%	—	12.1%
Div. Yield	0.1%	—	2.5%●	0.0%	0.2%
Payout	-2.0%	—	103.1%	0.0%	0.0%

Valuation
Metric	RYTM	IMVT	PCVX	MIRM	TGTX	SRRK	Ind. Median
P/E	—	—	—	—	18.47	—	17.91
P/B	63.14	9.27	2.72●	30.48	14.63	25.31	3.51
EV/EBITDA	—	—	—	—	58.41	—	14.82
P/S	35.74	—	—	12.98	12.18●	—	10.89

Financial Health
Metric	RYTM	IMVT	PCVX	MIRM	TGTX	SRRK	Ind. Median
Current Ratio	4.17	9.09●	7.49	2.09	5.81	8.64	5.90
Debt/Equity	184.7%	0.0%●	3.9%	133.5%	129.2%	74.5%	10.9%
NetDebt/EBITDA	0.63	1.79	1.76	0.08●	1.59	0.69	1.15

Profitability
Metric	RYTM	IMVT	PCVX	MIRM	TGTX	SRRK	Ind. Median
Net Margin	-93.3%	—	—	-140.2%	66.0%●	—	-125.7%
ROE	-141.7%	-64.8%	-30.6%	-335.8%	112.6%●	-138.9%	-47.5%
ROA	-48.9%	-58.3%	-28.1%	-101.0%	42.3%●	-86.7%	-35.8%
EBITDA Margin	-83.2%	—	—	-133.6%	21.4%●	—	-105.8%

Growth + Dividend
Metric	RYTM	IMVT	PCVX	MIRM	TGTX	SRRK	Ind. Median
Rev. Growth	58.7%	-100.0%	—	50.2%	81.3%●	—	5.1%
NI Growth	—	—	—	—	1,079.8%	—	12.1%
Div. Yield	0.1%●	—	—	—	0.0%	—	0.2%
Payout	-2.0%	—	—	—	0.0%	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RYTM

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.